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INTRODUCTION
During the past decade, treatment with donor lympho-
cyte infusion (DLI) has become increasingly common after
allogeneic hematopoietic stem cell transplantation (HSCT).
Early reports documented complete hematologic, cytoge-
netic, and molecular responses in patients with chronic
myelogenous leukemia (CML) [1-3]. Subsequent studies
conﬁrmed that DLI can induce durable remissions in 70%
to 80% of patients who have relapses of CML after trans-
plantation [4,5]. Activity also has been noted with other
malignant diseases, including multiple myeloma, myelodys-
plasia (MDS), and chronic lymphocytic leukemia (CLL)
[5-8]. Chimerism analysis has demonstrated that DLI can
convert mixed recipient/donor-derived hematopoiesis to full
donor hematopoiesis [9,10]. As a consequence, the use of
DLI in the absence of overt disease relapse has been
explored after nonmyeloablative allogeneic transplantation
and after T-cell–depleted (TCD) HSCT [11-15].
Graft-versus-host disease (GVHD) is the most common
complication of DLI. GVHD has been reported in 30% to
75% of patients receiving DLI [4,5,16]. In many cases,
GVHD has been severe and has led to non–relapse-related
mortality. In some series, GVHD has been closely associ-
ated with induction of graft-versus-leukemia (GVL) activity.
However, disease responses have been observed in patients
in whom GVHD did not develop. This observation has led
investigators to explore approaches that could limit GVHD
without compromising GVL. There are reports that graded
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ABSTRACT
The application of DLI is limited by the potential development of GVHD. Results of single-arm trials suggest that
CD8+ depletion of DLI may reduce the incidence of GVHD while still inducing pathologic and cytogenetic remis-
sions. To test the impact of CD8 depletion on GVHD, we initiated a randomized trial comparing outcome among
patients receiving unselected donor lymphocytes or CD8+-depleted cells. DLI was administered to patients with dis-
ease in remission to prevent relapse 6 months after T-cell–depleted allogeneic BMT. CD8 depletion was performed
with monoclonal antibody and rabbit complement. Donor lymphocytes obtained from the original donor were
infused fresh without cryopreservation. Infusions were adjusted so that all patients received 1.0 × 107 CD4+ cells/kg.
Patients randomized to CD8 depletion received a median of 0.7 × 105 versus 32.0 × 105 CD8+ cells/kg in the unma-
nipulated cohort. Six (67%) of 9 patients receiving unselected DLI developed acute GVHD compared with 0 (0%) of
9 recipients of CD8-depleted DLI (P = .009). In the unselected group, 2 patients died while the disease was in
remission, and 3 patients had relapses. In the CD8-depleted cohort, there were no toxic deaths and only 1 relapse.
Measures of immunologic reconstitution by T-cell receptor excision circle analysis and T-cell receptor spectratyp-
ing demonstrated similar patterns of T-cell recovery in both the CD8-depleted and the unselected cohorts. Both
groups converted from mixed to full donor hematopoietic chimerism after DLI. Our results indicate that CD8
depletion reduces the incidence of GVHD associated with DLI without adversely affecting conversion to donor
hematopoiesis or immunologic recovery.
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administration of smaller numbers of lymphocytes can
retain GVL activity with a lower incidence of GVHD
[17,18]. In addition, several groups have examined the
effects of selective infusion of T-cell subsets on GVHD. In
particular, results of single-arm phase I and phase II studies
have suggested that CD8 depletion of DLI can reduce
GVHD incidence without compromising GVL activity
[7,19]. These studies were based on earlier clinical and cor-
relative laboratory studies that implicated CD8+ T-cells as
major contributors to GVH reactions [20,21].
In this report, we describe the results of a randomized
study of CD8 depletion of DLI following TCD allogeneic
HSCT. DLI was administered as prophylaxis against relapse
5 to 7 months after TCD HSCT. Randomized patients
received equivalent numbers of CD4+ T-cells. Our results
indicated that CD8 depletion was associated with a decreased
incidence of GVHD. Moreover, CD8 depletion did not
appear to hamper conversion to full donor chimerism, nor
did it appear to compromise immunologic recovery.
METHODS
Patient Selection
Patients were eligible for enrollment if they had under-
gone TCD allogeneic bone marrow transplantation (BMT)
for hematologic malignant disease and were 5 to 7 months
posttransplantation. Patients with active GVHD or those
who were taking systemic immunosuppressive medications
were not eligible. Patients with uncontrolled active infection
and those who had received treatment for disease relapse
after transplantation also were excluded. All patients received
treatment with protocol 98-019, which was approved by the
Scientific Review Board and Human Subjects Protection
Committee at Dana-Farber Cancer Institute (DFCI).
BMT Protocol
All patients received cyclophosphamide 60 mg/kg intra-
venously × 2 (days –5 and –4) on 2 consecutive days fol-
lowed by TBI for ablation. TBI was administered at a dose
of 1400 cGy given twice daily in equal 200-cGy fractions on
days –3, –2, and –1 and once on day 0. All patients were
treated in a dedicated facility with opposing anteroposte-
rior/posteroanterior fields at a dose rate of 10 cGy/min.
Donor bone marrow was harvested on the last day of TBI
administration and transported to the cell manipulation lab-
oratory at DFCI, where the marrow was processed. Mono-
nuclear cells were isolated from marrow by Ficoll-Hypaque
centrifugal sedimentation. This product was then depleted
of CD6+ T-cells by complement-mediated antibody lysis
with anti-T12 monoclonal antibody as previously described
[22]. No patients received prophylactic immunosuppressive
therapy to prevent development of GVHD. After discharge,
administration of trimethoprim-sulfamethoxazole (or an
alternative agent) was resumed to prevent Pneumocystis
carinii infection. Acyclovir was administered for herpes sim-
plex and herpes zoster prophylaxis.
DLI Administration
Five to 7 months after BMT, participating patients
received DLI. Enrolled patients were randomized to receive
either CD8-depleted or unmanipulated donor lymphocytes.
For patients randomized to the CD8-depleted arm, CD8+
cells were purged from the donor leukopheresis product by
complement-mediated lysis with monoclonal antibody 2T8
and rabbit complement as previously described [7]. The
total numbers of CD4+ and CD8+ cells present after purging
were determined by ﬂuorescence-assisted cell sorter analy-
sis. For patients randomized to receive unselected lympho-
cytes, mononuclear cells were isolated by density gradient
centrifugation, and the numbers of CD4+ and CD8+ cells
present after isolation were calculated without depletion.
For patients receiving unselected donor lymphocytes and
those receiving CD8-depleted donor lymphocytes, the num-
ber of total cells infused was adjusted so that all patients
received 1 × 107 CD4+ cells/kg.
Clinical Evaluation
Data were evaluated as of July 1, 2002. Acute GVHD
and chronic GVHD were graded according to established
criteria [23]. Remission status was assessed with disease-
appropriate criteria (bone marrow evaluation, physical
examination, computed tomography) at approximately 6 and
12 months post-BMT and then yearly or as clinically indi-
cated thereafter.
Immunophenotypic Recovery
Prior to DLI and at regular intervals thereafter, periph-
eral blood mononuclear cells (PBMC) (0.5-1 × 106) were
isolated by Ficoll-Hypaque centrifugal sedimentation and
were incubated at 4°C for 30 minutes with a panel of murine
monoclonal antibodies speciﬁc for CD3, CD4, CD8, CD20,
and CD56 antigens conjugated to ﬂuorescein or phycoery-
thrin (Beckman Coulter, Hialeah, FL) for assessment of
recovery of T-cells, B-cells, and natural killer cells. Antibod-
ies were used at 1:100 dilution, and cells were washed with
phosphate-buffered saline followed by fixation with 2%
paraformaldehyde. Immunophenotypic analysis of the stained
and fixed cells was performed with a Beckman Coulter
EPICS XL ﬂow cytometer.
Lymphohematopoietic Chimerism
We assessed the degree of host chimerism in recipients
of unmanipulated and CD8-depleted DLI before planned
DLI and at regular intervals after DLI. Genomic DNA was
extracted from samples of each donor-recipient pair before
transplantation and ampliﬁed by polymerase chain reaction
(PCR) with a panel of 6 primer pairs speciﬁc for polymor-
phic microsatellite regions for identiﬁcation of an informa-
tive locus as described previously [9]. The amplification
products were electrophoresed on an automated 373 or 377
DNA sequencer (Applied Biosystems, Foster City, CA) with
a 4.75% or 4% polyacrylamide gel, respectively. The data
were analyzed with GeneScan software (Perkin Elmer
Cetus, Norwalk, CT). A locus was deﬁned as informative if
analysis of recipient and donor samples before transplanta-
tion showed either a unique band for the recipient and a
unique band for the donor or if it showed a unique band for
the recipient only. Once an informative locus was identi-
fied, genomic DNA from subsequent samples at various
time points was ampliﬁed with that speciﬁc primer to follow
hematopoietic chimerism. For quantiﬁcation of the donor-
to-recipient ratio in mixed chimeras, results were referred
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to standard amplifications of different mixtures of donor
and recipient pretransplantation DNA (ranging from 90:10
to 10:90) [9,10].
Assessment of T-Cell Neogenesis
T-cell receptor excision circles (TRECs) were quantiﬁed
with real-time PCR (ABI 7700; Perkin-Elmer) from
genomic DNA obtained before and at regular intervals after
DLI [24]. The PCR primer sequences were sense 5′-CGT
GAG AAC GGT GAA TGA AGA GCA GAC A-3′ and
antisense 5′-CAT CCC TTT CAA CCA TGC TGA CAC
CTC T-3′. The probe sequence was 5′-VIC-TTT TTG
TAA AGG TGC CCA CTC CTG TGC ACG GTG A-
TAMRA-3′. Each 50 µL of reaction mixture contained
0.075 µg DNA and the following concentrations of other
components: 1× Taqman buffer A (Perkin-Elmer), 3 mM
MgCl2, 300 nmol each primer, 100 nmol probe, 200 nmol
deoxyadenosine triphosphate, deoxycytidine triphosphate,
and deoxyguanosine triphosphate, 400 nmol deoxyuridine
triphosphate, 17 units uracil-DNA glycosylase, and 2 units
AmpliTaq Gold DNA polymerase (Perkin-Elmer). One
cycle of denaturation (95°C for 10 min) was performed and
followed by 50 cycles of ampliﬁcation (94°C for 30 seconds,
60°C for 30 seconds). TRECs were quantified with real-
time PCR (ABI 7700; Perkin-Elmer) from blood obtained
before and at regular intervals after DLI [24]. Each patient
and each control DNA sample were assessed in duplicate on
a 96-well plate with the dilution series of the TREC plasmid
as well as a dilution series of a glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) plasmid. The GAPDH copy
number served as a control for both the quality and amount
of genomic DNA in the sample. 
Spectratyping
For assessment of the diversity of the T-cell repertoire
with CDR3 spectratyping, RNA was extracted from PBMC
obtained from patients at different points before and after
DLI. First-strand complementary DNA (cDNA) was gener-
ated from 2 µg total RNA with random hexanucleotides
(Pharmacia LKB Biotechnology, Picscataway, NJ) and
reverse transcriptase (Superscript; GIBCO BRL, Gaithers-
burg, MD). Each T-cell receptor (TCR) V segment was
ampliﬁed with 1 of the 26 V subfamily-speciﬁc primers and a
C primer recognizing both C1 and C2 regions. The C primer
was conjugated to ﬂuorescent dye 6-FAM (Applied Biosys-
tems). The size distribution of each ﬂuorescent PCR prod-
uct was determined by electrophoresis on an automated 373
or 377 DNA sequencer (Applied Biosystems).
The overall complexity within a Vβ subfamily was deter-
mined by counting the number of discrete peaks per subfam-
ily. Subfamilies were graded on a score of 0 to 8 according to
degree of complexity. Normal complexity was characterized
by a Gaussian distribution of transcript sizes, which reﬂect
the presence of polyclonal cDNA species and contain 8 to
10 peaks for each V subfamily. A score of 0 was assigned if a
subfamily was absent. A score of 1 was given if a subfamily
demonstrated only a single monoclonal peak. A score of
2 was given for a biclonal profile. A subfamily was desig-
nated with a score of 3 if 3 peaks were present, and so on.
A score of 8 denoted a normal-appearing spectratype of 8 to
10 peaks with a complex, diverse, and polyclonal appear-
ance. The overall spectratype complexity score per sample
was calculated as the summation of the number of subfami-
lies (ie, 26, because subfamilies 5 and 13 are represented by
2 sets of primers) per score category with a maximum possi-
ble score of 208 (8 × 26) [10,25].
Statistical Considerations
Event-free survival was measured from the date of bone
marrow infusion to the ﬁrst of relapse, progression, or death
in remission. Patients were censored at the date on which
they were last seen and reported without disease. Overall
survival was measured from the date of bone marrow infu-
sion to the date of death or date last known alive. Event-free
survival and overall survival were calculated by the method
of Kaplan and Meier [26]. The Fisher exact test was applied
for comparison of the incidence of acute or chronic GVHD
in the 2 randomized arms [27]. The Fisher exact test also
was used for comparison of donor chimerism, TREC quan-
tification, and immunophenotypic PBMC analysis before
and after DLI in the 2 randomized groups. The study was
initially powered to detect a difference in GVHD incidence
of 20% with a planned accrual of 76 patients but was termi-
nated early because of interruption in the availability of
anti-CD6 monoclonal antibody to perform T-cell depletion
at the time of initial BMT.
RESULTS
Patient Characteristics
Eighteen patients were accrued to the study, 9 in the
CD8-depleted and 9 in the unmanipulated arm (Table 1).
The median age of both groups was 47 years. There were
6 female patients and 3 male patients in each arm. In the
CD8-depleted arm, 6 patients had undergone transplanta-
tion for MDS/AML, 2 for ALL, and 1 for myeloﬁbrosis. In
the unmanipulated arm, 5 patients had undergone transplan-
tation for MDS/AML, 2 for CLL, and 1 each for ALL and
non-Hodgkin’s lymphoma. The median follow-up period for
both groups was 24 months post-DLI (range, 9-39 months).
DLI Administration
Donor lymphocytes were obtained from the original
donor in 1 (n = 16) or 2 (n = 2) leukapheresis sessions and
were infused fresh without cryopreservation in the outpatient
clinic. Administration occurred a median of 184 days after
BMT. Two patients (1 in each arm) developed fevers within
Table 1. Patient Characteristics
CD8-Depleted Unselected
DLI DLI
Median age, y 47 47





Non-Hodgkin’s lymphoma 0 1
Myelofibrosis 1 0
Median follow-up post-DLI (range), mo 30 (25-42) 30 (26-41)
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24 hours of administration. There were no other infusion-
related toxicities. All patients received 1.0 × 107 CD4+
cells/kg. Patients randomized to CD8 depletion received a
median of 0.7 × 105 (range, 0.0-3.6 × 105) CD8+ cells/kg
compared with 32.0 × 105 (range, 15.5-36.4 × 105) CD8+
cells/kg in the unmanipulated cohort. The median numbers
of CD3+ cells/kg infused were 1.08 × 107 (range, 1.02-1.14 ×
107) and 1.56 × 107 (range, 1.26-2.02 × 107), respectively, in
the CD8-depleted and unmanipulated groups.
Graft-versus-Host Disease
Six (67%) of 9 patients receiving unselected DLI devel-
oped acute GVHD compared with 0 (0%) of 9 recipients of
CD8-depleted DLI (P = .009) (Table 2). The median onset
of acute GVHD was day +44 after DLI. (range, 38-62 days).
Acute GVHD was scored as grade I (n = 1), grade II (n = 2),
grade III (n = 3), or grade IV (n = 1). All 6 patients needed
systemic steroid therapy. No other patients in either arm
were treated with systemic steroids or other immunosup-
pressive medications. Chronic GVHD was identified in
3 patients in the unselected group (2 cases of extensive dis-
ease, 1 case of limited disease) and in 1 patient in the CD8-
depleted arm (limited disease).
Patient Outcome
Relapse of the underlying malignant disease for which
patients underwent transplantation was documented in 4 of
the 18 patients. Three of these patients (1 with MDS, 1 with
CLL, and 1 with ALL) had received unmanipulated DLI.
One patient receiving CD8-depleted DLI suffered a relapse
of ALL (Table 2). Two patients, both of whom received
unmanipulated DLI, died while the disease was in remission,
1 of grade IV GVHD and 1 of pneumonitis. The estimated
2-year relapse-free survival rate post-BMT in the CD8-
depleted group was 88% compared with 40% among the
patients who received unselected DLI (P = .08) (Figure 1).
Hematopoietic Chimerism
Six months after CD6+ TCD BMT, immediately before
DLI, patients in both groups had an average of 60% donor
cells by hematopoietic chimerism analysis with microsatel-
lite polymorphisms. Conversion to full donor chimerism
occurred at a similar pace after DLI in both cohorts. By
12 months after DLI, an average of 98% of hematopoietic
cells were of donor origin in both groups (Figure 2).
Immunologic Recovery after DLI
Phenotypic Analysis of Peripheral Blood. Immunophenotypic
analysis of peripheral blood samples up to 18 months post-
DLI revealed similar proﬁles. There were no signiﬁcant dif-
ferences in the percentage of CD4+ T-cells (RO and RA),
CD8+ T-cells (RO and RA), and CD20+ B-cells in patients
receiving depleted or unmanipulated DLI (data not shown).
Of note was an actual dip in the number of circulating CD4+
and CD8+ T-cells early after DLI with eventual recovery and
increase by 6 months after infusion. In contrast to the pat-
tern of T-cell recovery after both CD8-depleted and unse-
lected lymphocyte infusions, there was a steady increase in the
absolute number of circulating B-cells after DLI (Figure 3).
This pattern of recovery differed from that observed in
patients who had not received DLI after CD6-depleted allo-
geneic BMT [28]. The increase in B-cell number is of interest
Table 2. GVHD, Relapse, and Survival after DLI
Median CD4/kg Median CD8/kg Alive, NED,
DLI (range), ×107 (range), ×107 Acute GVHD* Chronic GVHD Relapse at 24-mo F/U†
Unselected (n = 9) 1.0 0.320 (0.155-0.364) 6/9 3/9 3/9 4/9
CD8-depleted (n = 9) 1.0 0.007 (0.000-0.036) 0/9 1/9 1/9 8/9
*P = .009. 
†NED indicates no evidence of disease; F/U, follow-up.
Figure 1. Event-free survival after transplantation as a function of
time for patients who received CD8-depleted (dashed line) or unma-
nipulated (solid line) DLI.
Figure 2. Lymphohematopoietic chimerism. Mean percentage (±SE)
of donor-derived bone marrow cells before and at regular intervals
after CD8-depleted or unmanipulated DLI.
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because there have been reports of induction of humoral
responses as a consequence of cellular therapy in patients
with CML [29]. B-cell and associated serologic responses to
speciﬁc antigenic determinants after DLI merit further study
for determination of the contribution of humoral immunity
to DLI-associated antitumor activity.
Recovery of TCR Diversity. We have previously demon-
strated that reconstitution of TCR diversity following TCD
transplantation is related to the degree of hematopoietic
chimerism. To quantify changes in TCR repertoire in
response to DLI, we used an 8-point scoring system for each
Vβ subfamily identiﬁed by PCR ampliﬁcation. As reported
previously, 6 months after transplantation patients demon-
strated skewed repertoires consisting of absent, monoclonal,
or oligoclonal proﬁles for many Vβ subfamilies. After DLI
administration, the proﬁle for patients became more diverse
with polyclonal spectratypes. As shown in Figure 4, complex-
ity scores recovered in a similar fashion for patients receiving
either CD8-depleted or unselected DLI. In future studies, it
would be enlightening to examine TCR diversity in CD4
and CD8 subpopulations to determine whether there is evi-
dence of skewing in any subset.
Measures of T-Cell Neogenesis. Normal TCR gene
rearrangement in T-cell progenitors leads to the generation
of TREC [30,31]. Quantitation of TRECs can be used as a
measurement of T-cell neogenesis posttransplantation. We
have previously demonstrated that CD8-depleted DLI can
correct abnormally low TREC levels in patients who have
relapses posttransplantation [24]. Prior to BMT for patients
in this study, the median TREC counts in PBMC were 1.8 ×
104 TRECs per microgram DNA in the unselected group
and 2.9 × 103 TRECs per microgram DNA in the CD8-
depleted group. TREC counts were noted to be substan-
tially depressed after BMT at the time of DLI (Figure 5).
TREC values increased steadily after DLI in patients
who received either CD8-depleted or unselected cells. By
7 months to 1 year after DLI, TREC counts had increased
back toward the normal range (5.25 × 103 TREC per micro-
gram DNA and 5.25 × 103 TREC per microgram DNA).
Thirteen to 18 months post-DLI, TREC counts had
increased further (2.8 × 104 TREC per microgram DNA
and 5.5 × 104 TREC per microgram DNA) into a range that
indicated a return to normal levels of adult thymic function
[32]. Despite differences in starting TREC counts between
the CD8-depleted and nondepleted groups, the return of
thymic function did not appear to be affected by CD8
depletion. In Figure 6, recovery of CD4+ and CD8+ cells is
displayed with TREC values and TCR diversity scores in a
representative patient before and after infusion of CD8-
depleted DLI.
DISCUSSION
The therapeutic application of DLI is limited by the
potential development of GVHD. Several strategies have
been proposed to control the incidence and severity of
GVHD associated with DLI. These have included graded
infusions of limited numbers of lymphocytes, selective
depletion of lymphocyte subsets, and genetic manipulation
of cells to regulate their sensitivity to agents such as ganci-
clovir [7,17,19,33,34]. If DLI is to become established as a
valuable clinical modality for either the treatment or the
prevention of relapse posttransplantation, it is critical that
GVHD be minimized.
Our data suggest that CD8 depletion can decrease the
incidence of GVHD associated with donor lymphocyte
administration. Six of 9 patients receiving unmanipulated
DLI developed acute GVHD compared with none of the
patients receiving CD8-depleted cells. CD8 depletion has
previously been explored in a number of transplantation set-
tings. Single-arm trials of CD8-depleted DLI for patients
who had relapses after transplantation have been associated
with GVHD rates of 10% to 35%, lower than the rate
reported after infusion of unselected donor lymphocytes.
However, the number of cells infused varied in these studies,
as did the interval between transplantation and DLI, both
factors that could inﬂuence the development of GVHD. In
our study, all patients received cells approximately 6 months
posttransplantation. In addition, the number of CD4+ T-cells
was held constant in the 2 groups; only the number of CD8+
Figure 3. Immunophenotypic reconstitution. Absolute number of cir-
culating cells expressing CD4, CD8, CD3, and CD20 after DLI. There
was no significant difference in recipients of CD8-depleted or unse-
lected lymphocytes at any time point.
Figure 4. TCR repertoire diversity. Overall spectratype complexity
(Vβ) score before and after DLI in both cohorts of patients. The range
of complexity scores for healthy volunteers also is displayed.
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cells varied. The current study is the ﬁrst demonstration in a
randomized trial that CD8 depletion reduces GVHD after
DLI. Although the number of patients actually enrolled in
the trial was relatively small, the marked difference in GVHD
incidence is sufﬁciently striking to support this conclusion.
The prophylactic nature of the trial and heterogeneity
of patients enrolled preclude any definitive conclusions
about the comparative capacity of CD8-depleted and unse-
lected DLI to prevent disease relapse. However, fewer
relapses (1 versus 3) were observed in the CD8-depleted
arm. This ﬁnding supported the notion that CD8 depletion
does not impair efﬁcacy. There is evidence that CD4+ T-cell
clones can mediate antileukemic activity in vivo [35,36].
Also encouraging was the observation that CD8 depletion
did not compromise the ability of DLI to convert patients
from mixed to full donor hematopoietic chimeras. Prior
studies have demonstrated that full donor chimerism is asso-
ciated with freedom from relapse posttransplantation [37].
Our data conﬁrm that conversion to full donor chimerism
can be achieved without the development of GVHD.
CD8 depletion does not appear to hinder immunologic
reconstitution promoted by DLI. T-cell neogenesis as
Figure 5. T-cell neogenesis. Recent thymic emigrants as measured by TREC assays are compared in patients before and after CD8-depleted or
unmanipulated DLI.
Figure 6. T-cell recovery. Recovery of CD4+CD45RO+ and CD8+CD45RO+ cells is displayed with TREC values and TCR diversity scores in a
representative patient before and after infusion of CD8-depleted DLI.
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measured by TREC analysis recovered at a similar pace in
both cohorts of patients. Similarly, studies of TCR spec-
tratyping revealed normalization complexity scores in each
group. Restoration of immunologic function may be less a
direct function of the actual immune effectors infused and
more a consequence of the suppression of recipient-derived
hematopoiesis.
The most appropriate time to administer CD8-depleted
DLI is not clear. The antileukemic activity of CD8-depleted
DLI for relapsed disease has been demonstrated in phase II
studies. Although a reduced incidence of GVHD would
make CD8 depletion logical in this setting, a randomized
study would be helpful to conﬁrm that antileukemic efﬁcacy
is not compromised. In the current study, DLI was adminis-
tered to prevent relapse after TCD BMT. Whether DLI can
perform this function after either TCD BMT or nonmye-
loablative transplantation needs to be established. If there
turns out to be a role for DLI in these circumstances, a
CD8-depleted lymphocyte product that can limit GVHD
would be an attractive option.
The low incidence of GVHD associated with CD8 deple-
tion may depend on the total number of cells infused. In our
previous trials of CD8-depleted DLI, GVHD was observed
in some patients receiving higher doses of cells, 3 to 15 × 107
CD4 cells/kg. In the current trial, patients in the CD8-
depleted group received only 1 × 107 CD4 cells/kg and only
0.7 × 105 CD8 cells/kg. We chose to reduce the dose of CD4
cells administered in this protocol because of the prophylactic
setting of therapy. We speculated that lower cell numbers
might provide sufficient immunologic activity to prevent,
rather than treat, relapse. At higher cell doses of CD4 or
CD8 cells, it is not certain that the same benefits of CD8
depletion would be observed. It is unclear whether there is a
threshold number of CD8+ cells required to induce GVHD.
If CD8 depletion can reduce GVHD without interfering
with antileukemic activity, this approach might be useful as a
primary form of GVHD prophylaxis during transplantation
itself. CD8 depletion of bone marrow has been evaluated in
clinical trials [20]. A randomized trial showed a lower inci-
dence of GVHD without a significant increase in relapse
rates [38]. However, the transplantation-related mortality in
this trial was substantial in these patients, thus no overall
advantage was observed. Several experimental studies have
raised concerns that CD8 depletion of bone marrow might
hinder hematopoietic engraftment [39]. Allogeneic periph-
eral blood stem cell transplantation (PBSCT), in which
engraftment is accelerated and transplantation-related mor-
tality is reduced, might be a very reasonable area in which to
again test CD8 depletion as an approach to primary GVHD
prophylaxis [40,41]. We have recently initiated such a trial at
our institution. The introduction of simpler approaches to
CD8 depletion (high-density antibody-coated microparti-
cles) may allow large-scale multicenter trials in which this
approach can be deﬁnitively tested with DLI and PBSCT.
Our experience makes it tempting to entertain the con-
clusion that CD8+ T-cells mediate GVHD whereas CD4
cells mediate GVL activity. However, this interpretation of
our results would be oversimplified and likely inaccurate.
There is a complex interaction between CD4+ and CD8+
T-cells as well as other cellular components, such as B-cells
and dendritic cells, which drive GVH and GVL reactions
[42-45]. Our data, however, do raise the possibility that by
manipulating the balance of CD4 and CD8 cells, we may be
able to control GVH activity without compromising
immune reconstitution and GVL.
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